27oct09-thommed

  • July 2020
  • PDF

This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA


Overview

Download & View 27oct09-thommed as PDF for free.

More details

  • Words: 1,525
  • Pages: 3
DMG Research

October 27, 2009

SINGAPORE EQUITY Investment Research FY09 Results Review

Private Circulation Only

HEALTHCARE BUY Price Target

Maintain S$0.62 S$0.78

Lynette Tan +65 6232 3895 [email protected]

THOMSON MEDICAL CENTRE

Terence Wong, CFA +65 6232 3896 terence.wong @dmgaps.com.sg

TWCC and Vietnam hospital to support growth

Stock Profile/Statistics Bloomberg Ticker STI Issued Share Capital (m) Market Capitalisation (S$m) 52 week H | L Price (S$) Average Volume (3m) ‘000 YTD Returns (%) Net gearing (x) Altman Z-Score ROCE/WACC Beta (x) Book Value/share (S¢)

THOM SP 2694.50 291.98 181.03 0.63 0.37 190.68 27.84 Net cash 6.49 0.91 0.74 38.12

Major Shareholders (%) T Holdings Pte Ltd Harilela Hari Naroomal Cheng Wei Chen Credit Suisse Group

19.98 34.75 16.21 5.01

Share Performance (%) Month 1m 3m 6m 12m

Absolute 5.1 12.7 45.9 53.1

Relative 2.6 8.2 -2.3 -8.6

6-month Share Price Performance S$ 0.65

0.60

Thomson Medical’s FY(Aug)09 earnings came in within our expectations. Revenue achieved was S$67.4m (+11.8%), on the back of a record number of baby deliveries (8,907 babies) during the year and contribution from its Thomson Women’s Cancer Centre (TWCC). Net profit for FY09 grew by 14.2% YoY to S$12.8m. Going ahead, we expect its TWCC and network of Thomson Women’s Clinics (TWC) to continue driving growth. FY10 will see maiden full-year contribution from TWCC and the opening of another TWC, which would contribute to growth. Its hospital project in Binh Duong, Vietnam (Hanh Phuc Hospital) which is likely to commence in 3Q FY10, will also boost earnings growth. Management declared total dividends of 2.8 S¢ per share (including 0.3 S¢ special and 1.0 S¢ interim) for FY09. It is trading at a decent yield of 4.5%. Based on its peer average (ex-Parkway) of 16x, we arrive at a 12-month target price of S$0.78. Maintain BUY. Attracting patients by being innovative. Thomson Medical is the first hospital in Singapore to launch an interactive and personalised pregnancy and baby website. Through this, it aims to deliver more value to mothers-to-be and attract more baby deliveries at its hospital. To cope with the increasing demand for its services, Thomson Medical will be adding two more operating theatres to its current four. As it starts to market its TWCC across the region, contribution from TWCC is expected to grow and boost overall Group performance in FY10. Tapping on the growing popularity of traditional Chinese medicine (TCM), Thomson Medical has also started offering TCM services to its patients. This would serve to complement its existing O&G services, allowing it to offer East and West treatments to patients. We think that these initiatives would help boost its branding and in turn, contribute to growth.

0.55

0.50

0.45

0.40 Apr-09

May-09

Jun-09

Jul-09

Aug-09

Sep-09

Oct-09

Hanh Phuc Hospital project slated to commence operations in 3Q FY10. The construction for this hospital will be completed within the next two months. Once in operation, Thomson Medical would receive hospital management fees for running the Hanh Phuc Hospital, which would contribute to revenue and earnings growth. Maintain BUY. We are estimating earnings of S$14.2m (+10.9%) for FY10. We arrive at a 12-month target price of S$0.78, based on 16x FY10 earnings. FYE 31 Aug (S$m) Turnover Net Profit % chg YoY EPS (S¢) DPS (S¢) Div Yield ROE ROA P/E (x) P/B (x)

FY07

FY08

FY09

FY10F

FY11F

52.4 9.5 39.8% 3.3 2.5 4.0% 11.1% 8.7% 19.2 2.0

60.3 11.2 18.0% 3.8 2.5 4.0% 11.1% 9.0% 16.3 1.7

67.4 12.8 14.2% 4.4 2.8 4.5% 11.6% 9.7% 14.3 1.6

77.0 14.2 10.9% 4.9 2.5 4.0% 12.4% 10.3% 12.9 1.5

88.5 16.0 12.5% 5.5 2.7 4.4% 13.0% 10.7% 11.4 1.4

Source: Company and DMG Estimates

DMG Research See important disclosures at the end of this publication

1

DMG Research

October 27, 2009

Year End 31 Dec (S$m) Income Statement

Cash Flow 2008

2009

2010F

2011F

60.3 (33.7) 1.0 (8.4) (5.1) (0.3) 13.8 (2.6) 0.0 11.2

67.4 (38.3) 2.1 (9.8) (5.5) (0.1) 15.7 (3.0) 0.1 12.8

77.0 (43.6) 1.5 (11.2) (6.2) (0.2) 17.4 (3.3) 0.1 14.2

88.5 (50.0) 1.3 (12.8) (7.3) (0.2) 19.6 (3.7) 0.1 16.0

2008

2009

2010F

2011F

Fixed Assets

109.0

106.9

109.6

112.2

Goodwill Non-Current Assets Inventories Trade and other receivables Cash and cash equivalents Current Assets

0.1 109.2 1.0 5.4 15.6 21.9

0.1 107.1 1.2 4.3 20.6 26.0

0.1 109.7 1.2 4.6 27.6 33.4

0.1 112.3 1.4 5.3 35.2 41.9

Total Assets

131.1

133.1

143.2

154.3

2.7 1.6 4.4 13.2

1.4 1.7 3.0 15.1

1.4 1.9 3.3 17.3

1.3 1.6 2.9 19.9

0.1 2.5 1.4 17.2 109.5

2.3 1.4 18.7 111.3

3.0 1.3 21.6 118.3

3.3 1.3 24.5 126.9

0.1

0.0

0.0

0.0

Revenue Cost of sales Other Operating Income Administration expenses Other operating expenses Financial income, net Profit Before Taxes Income Tax Expense Minority Interest Net Income Balance Sheet

Bank borrowings Deferred tax Non-current liabilities Trade and other payables Obligations under finance leases Provision for tax Bank borrowings Current Liabilities Net assets Minority interests

Share capital Reserves Shareholder’s equity

37.5

37.5

37.5

37.5

72.0 109.5

73.8 111.3

80.8 118.3

89.4 126.9

2008

2009

2010F

2011F

Profit Before Taxation Non-cash Items Changes in Working Capital Income Tax Paid Interest Paid Net cash from operations

13.8 3.3 (0.9) (2.2) (0.3) 13.7

15.7 3.9 2.8 (3.2) (0.1) 19.0

17.4 3.1 1.8 (2..3) (0.2) 19.9

19.6 3.1 1.7 (3.0) (0.2) 21.3

Acquisition of Fixed Assets Interest Received Others Net cash from investments Dividends Paid Proceeds from/(Repayment of) Loan Others Net cash from financing Net increase / (decrease) in cash Cash (beginning) Cash (end)

(3.3) 0.2 0.0 (3.1) (5.8)

(5.3) 0.1 (5.3) (7.3)

(6.0) 0.3 (5.7) (7.2)

(6.0) 0.4 (5.6) (8.0)

(4.5) (0.0) (10.3)

(1.4) (0.0) (8.8)

(7.2)

(0.1) (8.1)

0.3 15.2 15.4

5.0 15.4 20.4

7.0 20.4 27.4

7.6 27.4 35.0

Ratios 2008

2009

2010F

2011F

Growth & Margin (%) Revenue Growth EBIT Growth EBIT Margin Pretax Profit Growth Pretax Profit Margin

15.1 19.3 23.3 21.1 22.8

11.8 12.5 23.5 14.0 23.3

14.2 10.9 22.8 11.0 22.6

15.0 12.5 22.3 12.5 22.1

Tax rate Net Income Growth Net Income Margin

18.9 18.0 18.6

18.9 14.2 19.0

18.9 10.9 18.4

18.9 12.5 18.0

2008

2008

2009F

2010F

47.7

51.9

58.3

67.1

12.5 60.3

15.5 67.4

18.6 77.0

21.4 88.5

Revenue Breakdown Hospital Operations and Ancillary Services Specialised and Other Services Total

Source: Company and DMG estimates

DMG Research See important disclosures at the end of this publication

2

DMG Research

October 27, 2009

DMG & Partners Research Guide to Investment Ratings Buy: Share price may exceed 10% over the next 12 months Trading Buy: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain Neutral: Share price may fall within the range of +/- 10% over the next 12 months Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months Not Rated: Stock is not within regular research coverage

This research is for general distribution. It does not have any regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this research report. You should independently evaluate particular investments and consult an independent financial adviser before making any investments or entering into any transaction in relation to any securities or investment instruments mentioned in this report. The information contained herein has been obtained from sources we believed to be reliable but we do not make any representation or warranty nor accept any responsibility or liability as to its accuracy, completeness or correctness. Opinions and views expressed in this report are subject to change without notice. This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities, DMGAPS and its affiliates, their directors, connected person and employees may from time to time have interest and/or underwriting commitment in the securities mentioned in this report. DMG & Partners Securities Pte Ltd is a joint venture between OSK Securities Berhad (a subsidiary of OSK Investment Bank Berhad) and Deutsche Asia Pacific Holdings Pte Ltd (a subsidiary of Deutsche Bank Group). DMG & Partners Securities Pte Ltd is a Member of the Singapore Exchange Securities Trading Limited. DMG & Partners Securities Pte. Ltd. (RCB Reg. No. 198701140E)

Kuala Lumpur Malaysia Headquarters OSK Investment Bank Bhd. 20th Floor, Plaza OSK Jalan Ampang 50450 Kuala Lumpur Malaysia Tel : + (60) 3 2333 8333 Fax : + (60) 3 2175 3333

Hong Kong Hong Kong Office OSK Asia Securities Ltd. 1201-1203, 12/F, World-Wide House 19 Des Voeux Road Central, Hong Kong Tel : + (852) 2525 1118 Fax : + (852) 2537 1332

Singapore Singapore Office DMG & Partners Securities Pte. Ltd. #22-01 Ocean Towers 20 Raffles Place Singapore 048620 Tel : +(65) 6438 8810 Fax : +(65) 6535 4809

Jakarta

Shanghai

Jakarta Office Shanghai Office PT OSK Nusadana Securities OSK Asia Securities Ltd. Plaza Lippo, 14th Floor, Room 6506, Plaza 66 Jl. Jend. Sudirman Kav. 25. No. 1266 Nanjing Road (West) Jakarta 12920 Shanghai 200040 Indonesia China Tel : + (6221) 520 4599 Fax : + (6221) 520 4505

DMG Research See important disclosures at the end of this publication

3